Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition
====================================================================================

* Rachel A. Bender Ignacio
* Jessica Long
* Aparajita Saha
* Felicia K. Nguyen
* Lara Joudeh
* Ethan Valinetz
* Simon C. Mendelsohn
* Thomas J. Scriba
* Mark Hatherill
* Holly Janes
* Gavin Churchyard
* Susan Buchbinder
* Ann Duerr
* Javeed A. Shah
* Thomas R. Hawn

## Abstract

**Background** Although immune activation is associated with HIV acquisition, the nature of inflammatory profiles that increase HIV risk, which may include responses to *M. tuberculosis* (*Mtb*) infection, are not well characterized.

**Methods** We conducted a nested case-control study within the Step MRKAd5 HIV-1 vaccine study. PBMCs from the last HIV-negative sample from incident HIV cases and controls who did not acquire HIV were stimulated with *Mtb*-specific antigens (ESAT-6/CFP-10) and analyzed by flow cytometry with intracellular cytokine staining.

**Com**binatorial **p**olyfunctionality analysis of **a**ntigen-**s**pecific T-cell **s**ubsets (COMPASS) determined overall *Mtb*-antigen-specific T cell activation. We measured inflammatory profiles with five Correlates of TB Risk (CoR) peripheral blood transcriptomic signatures. Conditional logistic regression analyses, adjusted for known predictors of HIV acquisition, were employed to assess whether either cellular markers of TB-associated immune activation or transcriptomic predictors of TB disease states were associated with HIV acquisition.

**Results** Among 465 participants, latent *Mtb* infection (LTBI) prevalence (21.5% controls vs 19.1% cases, p=0.51) and *Mtb* antigen-specific polyfunctional CD4+ T cell COMPASS scores (aOR 0.96, 95% CI 0.77, 1.20) were not higher in those who acquired HIV. Two CoR signatures, Sweeney3 (aOR 1.38 (1.07, 1.78) per SD change) and RESPONSE5 (0.76 (0.60, 0.95)), were associated with HIV acquisition in multivariable analysis. The Sweeney3 signature best predicted odds of acquiring HIV in unadjusted and adjusted analyses, including when restricted to LTBI-negative participants.

**Conclusions** LTBI and *Mtb* polyfunctional antigen-specific CD4+ T cell immune activation were not identified as risk factors for HIV acquisition, but transcriptomic analyses demonstrated that two CoR signatures predicted HIV risk after adjustment for known behavioral and clinical risk factors. CoR signatures can demonstrate host gene expression associated with HIV acquisition, but the observed effects are likely not mediated through *Mtb* infection.

Keywords
*   HIV risk
*   *M. tuberculosis* infection
*   TB
*   immune activation
*   transcriptomics
*   epidemiology
*   immunology

## Background

Several lines of evidence suggest that systemic inflammation increases risk of HIV acquisition. For example, in the HIV Vaccine Trials Network Step Study (V520-023/HVTN 502), an efficacy trial of an Adenovirus 5 (Ad5)-vectored HIV-1 vaccine, some vaccinees experienced a *transient* increased risk of HIV acquisition for several months after vaccination.[1, 2] In Step, ELISpot mock responses (interferon-gamma [(IFN-□] secretion in the absence of antigen), but not HIV-antigen stimulated responses, directly correlated with a 61% increase in HIV acquisition risk.[3] Furthermore, CAPRISA-004 and Partners in Prevention studies each identified different cytokine profiles associated with HIV acquisition.[4, 5] Other studies suggest associations between herpes simplex virus-2 and chronic filarial infections with HIV acquisition.[6-8] Although there is some understanding of the local genital inflammation and microbiome changes associated with HIV susceptibility,[9-11] the biologic underpinnings of peripheral blood immune profiles potentially associated with HIV risk are not well understood. It may be that other infections or exposures induce immune phenotypes that increase susceptibility of CD4 T cells and macrophages to HIV infection.

*Mycobacterium tuberculosis* (*Mtb*) latently infects approximately 24% of the world’s population, with an estimated 10 million new cases of clinical disease (TB) in 2019 alone.[12-14] Latent *Mtb* infection (LTBI), is defined by a positive response to *Mtb* antigens (Purified Protein Derivative (PPD) skin test or an IFN-□ release assay (IGRA)) in the absence of clinical symptoms. Recent data indicates that many asymptomatic individuals have “incipient TB” with evidence of systemic inflammation,[15] which is associated with an increased risk of progression to clinical TB disease.[16, 17] While the effects of HIV on risk of LTBI progression have been intensively investigated, the effect of *Mtb* infection on risk of acquiring HIV has never been formally assessed, other than in ex-vivo experiments.[18-21] In a recent study, infant macaques were vaccinated with TB vaccines and then challenged with simian immunodeficiency virus (SIV) orally. Animals vaccinated with either an *Mtb*-SIV auxotroph vaccine or BCG vaccine demonstrated significantly increased SIV risk compared to placebo recipients. Both vaccines resulted in immune activation, which correlated with SIV acquisition.[22]

Because the global burden of *Mtb* infection is high and the lifetime risk of progression to active disease is only ∼10% in HIV-negative persons, no countries with co-endemic TB and HIV routinely treat LTBI in HIV-negative persons.[23] If treating LTBI were to reduce the risk of acquiring HIV, then targeting LTBI treatment to the subset of individuals most at-risk for HIV could prevent development of TB disease as well as decrease risk of HIV. We therefore designed a study of LTBI- and *Mtb*-associated immune activation using prospectively collected samples from an HIV vaccine trial to address this question. We included several Correlates of Risk (CoR) transcriptomic signatures that have been validated to predict TB-disease states, including incipient active TB and TB treatment success, based on differential human gene activation.

## Methods

### Study Population

We conducted a case control study nested within the completed Step study (V520-023/HVTN502). The Step study enrolled 3,000 high-risk HIV-negative males and females aged 18-45 who received the MRKAd5 HIV-1 gag/pol/nef vaccine at 34 study sites in the Americas, Caribbean, and Australia from 2004-2007. Participants received vaccine/placebo injection at 0, 4, and 26 weeks. HIV testing was done at 6-monthly visits for up to 4 years of in the Step study and the follow-on HVTN 504; stored blood from the prior visit was tested for HIV RNA to more precisely time HIV acquisition.[2] A total of 172 incident infections were diagnosed in men (3.3/100 person-years) and 15 infections in women (0.45/100 PY).[1] We identified as cases all participants within Step and HVTN 504 with incident HIV who had available peripheral blood mononuclear cells (PBMC) at the last study visit prior to HIV acquisition. Cases who acquired HIV before week 8 (first available PBMC) were excluded. Controls were selected as persons who did not acquire HIV during study follow-up, matched to cases 2:1 on study site and treatment arm, and with a pooled gender distribution similar to cases. We acquired PBMC from the study visit corresponding to that of their matched case. The following baseline variables from the Step study were assessed: age, gender, race/ethnicity, and study site; study treatment (vaccine/placebo); baseline Ad5 antibody titer, self-reported behavioral HIV risks: drug use, number and type of sexual partners, condomless sex, substance use; circumcision status and HSV-2 serostatus for males. Step participants were generally not eligible for TB prophylaxis and no prophylactic or therapeutic TB drugs were documented during study follow up. Because this ancillary study used only deidentified data and samples from the Step trial, the work described in this manuscript was determined not to be engaged in human subjects research by the University of Washington institutional review board. All participants who participated in the Step study and whose samples and data were used here gave specific informed consent for future use of stored samples at time of participation in the vaccine trial.

### Cell activation and flow cytometry

Cryopreserved PBMCs were thawed, washed and rested in RPMI 1640 media containing 10% heat-inactivated fetal bovine serum (FBS) overnight prior to antigen stimulation with a concentration of 2 × 106 cells /mL. PBMCs were counted with Guava easyCyte (Millipore) using Guava ViaCount reagent (Luminex) and GuavaSoft v.2.6 software. Samples with less than 66% viability were discarded. Cells were stimulated with a pool of early secretory *Mtb* antigen target-6 (ESAT-6) and culture filtrate protein (CFP-10) (BEI Resources). PMA (25ng/mL)/ionomycin (1ug/mL) was used as a positive control and DMSO (0.5%) was used as a negative control. In addition, costimulatory antibody anti-CD28/49d, cytokine secretion inhibitor Brefeldin A and Monensin were added to each stimulation cocktail. Cells were lysed and permeabilized with FACS Lyse and FACS Perm-II buffer and stained on a BD LSRFortessa with an antibody panel developed for analyzing CD4 and CD8 T-cell responses (ICS) including IFN-□, TNF, IL-2, and IL-17a [1] **(Table S1)**.[24] Flow cytometry data were analyzed in FlowJo™ v10.7. Each sample was compensated and gated manually.

### RNA Isolation and RT-PCR

Approximately 2 × 106 PBMCs from each sample were re-suspended in RNA*later* (Invitrogen) preservative and stored at -20°C for processing[25]. Total RNA was isolated using RNeasy spin columns (Qiagen) and cDNA templates for qRT-PCR were generated using Applied Biosystems high-capacity cDNA reverse transcriptase kits. qRT-PCR was performed with 44 primer-probe sets (**Table S2**) from Taqman using the Fluidigm 96.96 dynamic array platform. cDNA was preamplified using a pool of specific TaqMan primer-probe sets for 16 cycles with a 15 second denaturation step at 95°C and 4 minutes at 60°C. The pre-amplified reaction was added to the Fluidigm 96.96 dynamic array platform with TaqMan gene expression assays and amplified for an additional 40 cycles. A positive control sample was run on every chip to monitor consistency. Primer-probe sets were included to encompass the components of 5 previously described CoR signatures from peripheral blood associated with TB disease outcomes. Signature scores were calculated from raw Ct values in R v3.6.1 as previously described.[25-30] (**Table S2**; additional primer probes not pertaining to selected CoRs were included for future analysis).

### Statistical Analysis

The outcome of interest in all analyses was HIV acquisition. To evaluate the association of *Mtb* antigen-specific T-cell activation and HIV acquisition, we used three measures: (1) Individuals with LTBI were defined using a flow cytometry-based method that is strongly correlated with the tuberculin skin test and IGRA. Samples were classified as positive if the frequency of IFN-□+ CD4+ cells stimulated with ESAT-6/CFP-10 pooled peptides doubled compared to negative control.[31-35]

(2) We used **Com**binatorial **p**olyfunctionality analysis of **a**ntigen-**s**pecific T-cell **s**ubsets (COMPASS) to determine overall *Mtb*-antigen-specific T cell activation. COMPASS is an analytic tool that uses a Bayesian hierarchical framework to model all observed cell subsets. COMPASS outputs functional scores (FS) and polyfunctional scores (PFS) that define the posterior probabilities of antigen-specific response across cell subsets, described by a single numerical score that ranges from 0 to 1.[36] We have previously used COMPASS to investigate polyfunctionality in CD4+ T cells in an epidemiologic study of South African adolescents screened for LTBI, as well as to predict HIV-specific responses in a prior HIV vaccine trial.[37, 38] FS and PFS derived from COMPASS output were included as untransformed variables.

(3) To determine whether transcriptomic evidence of *Mtb*-associated immune activation also predicts risk of HIV acquisition, we used Correlates of Risk (CoR) scores previously validated to detect different TB-associated states. The primary predictor of interest was RISK6, a 6-gene transcriptomic CoR signature that predicts progression to TB disease (incipient TB).[26] Additional CoR scores assessed in exploratory analysis include Suliman4 and Maertzdorf4, both of which predict incipient TB; Sweeny3, which accurately differentiates between LTBI and current active TB; and RESPONSE5, which predicts cure of at time of TB treatment initiation (**Table S2**).[27-30] CoR scores that were not normally distributed were log10 transformed (RISK6, Suliman4, and RESPONSE5) while the remaining scores were analyzed untransformed. To account for score values of zero (n=3; all RISK6), zeros were replaced by dividing the next lowest value by two.

For all measures, the association between exposures and HIV acquisition was estimated using univariate and multivariate conditional logistic regression accounting for the variables used to match controls to cases (country of residence and treatment arm within the Step study). Variables assessed for inclusion in multivariate regression included known predictors of HIV risk in the Step study (i.e. gender, validated behavioral risk score (scale 0-7)[39], baseline Ad5 titer, and self-reported race/ethnicity). Each variable of interest was assessed for association with HIV acquisition using conditional logistic regression, and associations that were significant at p<0.1 were included in the multivariate model. For sub-analyses restricted to males, we included HSV-2 serostatus and circumcision, as these were documented in the parent trial for males only. Analyses of the association of PFS, FS, and CoR scores with HIV acquisition were repeated after stratification by LTBI status. Stratified analyses were performed as standard logistic regression with matching variables included, as logistic regression conditioned on LTBI would have excluded all case/control sets with discordant LTBI status. PFS, FS, and CoR scores were reported as the Odds Ratio (OR) for 1 standard deviation change to allow for comparability across outcomes. As a sensitivity analysis, we repeated the primary analyses restricted to case/control sets with samples within 6 and 12 months prior to HIV diagnosis. Results for each set of analyses were controlled for false discovery using adjusted Benjamini-Hochberg p-values (α=0.05)[40]. All analyses were conducted in R v3.6.1 and Stata v15.1 (College Station, TX, USA, 2017).

## Results

We selected 155 cases who acquired HIV and 310 controls (n=465), with baseline characteristics presented in **Table 1**. Among cases, the median interval between sample collection date and HIV diagnosis was 287 days (IQR 161, 483). The majority of participants (88%) were from Peru or the US. By design, there was no difference in distribution of vaccine treatment arm or country in cases vs. controls, although there was a trend toward more males among cases. As expected, the behavioral risk score previously found to be associated with HIV acquisition was higher in cases (3.3 vs 2.8, SD 1.2, p<0.0001), and HSV-2 seropositivity was more common in male cases than controls (40.1% vs 30.7%, p=0.049).

View this table:
[Table 1:](http://medrxiv.org/content/early/2021/12/08/2021.12.08.21267470/T1)

Table 1: Participant Characteristics

To assess whether *Mtb* infection was associated with HIV acquisition, we examined 454 participants, including 152 cases and 302 controls (n=11 missing samples or gating failures). Overall, 94 (20.7%) of study participants were considered LTBI positive due to detection of ESAT-6-CFP-10-specific CD4+ T cells: 65 (21.5%) controls compared to 29 (19.1%) cases. LTBI positivity was not associated with HIV acquisition in unadjusted or adjusted conditional logistic regression analyses (aOR 0.85 (0.51, 1.43) per 1 SD change, p=0.73) (**Table 2**). When stratified by gender, the inference did not change. Among men, when adjusting for all covariates in the primary models as well as HSV-2, LTBI status was not associated with HIV acquisition (aOR: 0.99; 95% CI 0.58, 1.69). Likewise, there was no association between LTBI status and HSV-2 serostatus (31.8% seropositive in LTBI negative vs 30.0% in LTBI positive, p=0.77).

View this table:
[Table 2:](http://medrxiv.org/content/early/2021/12/08/2021.12.08.21267470/T2)

Table 2: LTBI status, *Mtb*-specific CD4 T-cell activation, and HIV acquisition.
Unadjusted and adjusted odds ratios for LTBI status, COMPASS polyfunctional scores (PFS) and functional scores (FS) in those who acquired HIV versus controls

ESAT-6/CFP-10-specific functional and polyfunctional cytokine expression, as measured through the COMPASS FS and PFS, respectively, were both significantly higher in LTBI-positive versus LTBI-negative samples (p<0.0001; **Figure 1A**). Among all 454 participants the mean FS was 0.035 (SD 0.047). Of 302 controls, the mean PFS was 0.035 vs 0.033 among 152 cases. **Figure 1B-D** shows box plots and a heatmap of COMPASS posterior probabilities by case/control status. The distributions of mono- and poly-functional *Mtb*-specific subsets across persons who did or did not acquire HIV were similar. When assessing the association using conditional logistic regression, neither FS (OR 0.94 per 1 SD change, 95% CI 0.76, 1.16) nor PFS (OR 0.96, 95% CI 0.78, 1.18) predicted HIV acquisition. Restricted to LTBI positive participants, we found no evidence of an association of FS or PFS with HIV acquisition (not shown).

![Figure 1:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2021/12/08/2021.12.08.21267470/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2021/12/08/2021.12.08.21267470/F1)

Figure 1: 
**Com**binatorial **p**olyfunctionality analysis of **a**ntigen-**s**pecific T-cell **s**ubsets (COMPASS) describes *Mtb*-antigen-specific T cell activation. Box and whisker plots depict median and interquartile ranges for FS and PFS scores as well as the range. **1A**. COMPASS Polyfunctional Scores (PFS) demonstrate expected higher levels of *Mtb*-specific cellular immune activation in persons with LTBI than those without (p<0.0001). **1B**. COMPASS *Mtb*-specific Functional Scores (FS) were no different between persons who acquired HIV and controls. **1C**. PFS was similarly indistinguishable between cases and controls. **1D**. Heatmap of COMPASS posterior probabilities depicts combinations of intracellular cytokine staining composing the combinatorial polyfunctional subsets of *Mtb*-specific CD4+ T cells. Columns show the subsets with detectable antigen-specific responses color-coded by the cytokines they express and ordered by the degree of functionality from one function on the left to 3 of 4 functions on the right; the combinations of cytokines are found in colored boxes at the bottom. Horizontal rows depict one participant, with lime shaded rows representing control samples stacked above violet rows representing persons who acquired HIV. The intensity of purple shading of each box shows the probability that a given participant sample that expresses the subset has a *Mtb*-antigen specific response ranging from white (zero) to purple (one). This heatmap depicts relatively similar distributions of mono- and polyfunctional *Mtb*-specific subsets across persons who did or did not acquire HIV.

RISK6 score was calculated for 439 participants (n=141 cases, n=298 controls) with successful RNA extraction. The mean of untransformed RISK6 scores among cases was 0.119 (SD 0.147) compared to 0.107 (SD 0.141) among controls (**Figure 2**). In both unadjusted and adjusted analyses, RISK6 was not associated with HIV acquisition (aOR 1.15 per 1 SD change, 95% CI 0.92, 1.44) (**Table 3**). **Figure 2** shows the distribution of CoR scores in cases who acquired HIV and controls for RISK6, as well as the other four CoR signatures (Suliman4, Sweeney3, Maertzdorf4, and RESPONSE5) examined in exploratory analyses. In multivariate conditional logistic regression, two of the four CoR measures demonstrated associations with HIV acquisition. A one SD increase of the Sweeney3 score was associated with a 38% increased odds of HIV acquisition (aOR 1.38, 95% CI 1.07, 1.78). In contrast, the RESPONSE5 CoR score was associated with a moderate decrease in odds of HIV acquisition (aOR 0.76, 95% CI 0.60, 0.95). There were no important trends in CoR scores between those who received HIV vaccine vs placebo, those with lower baseline Ad5 titer, gender, behavioral risk score, or HSV-2 serostatus in males. The mean of three CoR scores differed significantly by country of residence. Bivariate associations between predictors of HIV acquisition and each CoR are shown in **Table S3**. In adjusted analyses, HSV-2 serostatus (in males only) and Ad5 titer were not influential in evaluating associations between any CoR score and HIV acquisition.

View this table:
[Table 3:](http://medrxiv.org/content/early/2021/12/08/2021.12.08.21267470/T3)

Table 3: Associations between each Correlates of Risk (COR) signature and HIV acquisition, univariate and adjusted analyses

![Figure 2:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2021/12/08/2021.12.08.21267470/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2021/12/08/2021.12.08.21267470/F2)

Figure 2: Distribution of 5 TB Correlates of Risk (CoR) scores among participants who subsequently acquired HIV vs controls.
Box plots demonstrate median and interquartile range of values, with dots completing the range. RISK6, Suliman4, and RESPONSE5 were log10 transformed as this allowed for the data to be normally distributed and for all scores to be evaluable on a similar scale.

Due to the long interval between PBMC collection and HIV diagnosis in some cases, we performed sensitivity analyses including the 282 participants (n= 94, n= 188) with samples within 12 months, and then the 159 participants (n= 53, n= 106) with 6 months or less between sampling and HIV diagnosis. The aOR for RISK6 increased to 1.28 (0.94, 1.75) but neither this or any of the other primary exposures (LTBI, FS, or PFS), became statistically significant for participants sampled within a year of diagnosis. As in the full dataset, RESPONSE5 remained associated with decreased risk of HIV and Sweeney3 with the association strengthened by >10% (OR 1.56 (1.10, 2.21)). Due to loss of power, the point estimates for several exploratory analyses changed by >10% for the participants sampled within 6 months, but no findings were significant (**Table S4**).

In adjusted analyses stratified by LTBI status, a one SD increase in logRISK6 score was associated with a trend toward decreased odds of HIV acquisition among LTBI-positive participants (aOR 0.58, 95% CI 0.34, 0.99) and a trend toward increase in odds of HIV acquisition among LTBI negative participants (aOR 1.24, 95% CI 0.97, 1.59) (**Table S5**). Stratified by LTBI status, some associations between CoR scores and HIV remained in the LTBI negative participants, but not in the smaller subset of LTBI positive participants. In univariate analyses however, none of the CoR scores were associated with LTBI status (**Table S6**).

## Discussion

In this study, we accessed rare, cryopreserved specimens from the completed Step HIV vaccine trial to evaluate the influence of sub-clinical *Mtb* infection on HIV acquisition risk, employing a case-control design. Despite the fact that many of the biomarkers that have previously been associated with increased risk of acquiring HIV are also those elevated in subclinical/incipient *Mtb* infection or TB disease, we found little evidence that prior infection with *Mycobacterium tuberculosis* increases risk of acquiring HIV. To our knowledge, there are no cohorts in which LTBI status has been determined using clinical methods (TST or IGRA) among comparable persons with subsequent HIV endpoints. Our use of comprehensive flow cytometry and COMPASS analysis allowed us to retrospectively determine LTBI status and to characterize *Mtb* antigen-specific polyfunctional T-cell responses within a homogenous trial population with subsequent evaluation of HIV status. Neither LTBI status, nor polyfunctional cellular activation scoring was associated with risk of HIV acquisition, either bivariately, or after controlling for the previously described HIV risk factors. Transcriptional TB CoR signatures do not measure *Mtb*-specific responses, but rather the differential expression of genes associated with incipient or active TB disease; we hypothesized that these same signatures, many of which include interferon stimulated genes (ISGs), could also reveal HIV susceptibility states. However, the primary CoR signature of interest, the RISK6 signature, comprising several ISGs, did not predict HIV acquisition in the overall study. Although aORs differed by LTBI status, as RISK6 was associated with lower HIV risk in those with LTBI, and showed a trend towards increased HIV risk in those without LTBI, we could not rule out that this difference was due to chance. It is possible that pathways other than the specific ISG signaling characterized by RISK6 are associated with HIV risk and are also differentially regulated by co-infections. In addition, evaluation of other CoR profiles suggested associations with HIV acquisition, suggesting that there may be an unmeasured source of immune activation predictive of HIV acquisition, with the different gene sets in each signature describing different activation status and possibly various underlying exposures. Because LTBI was not independently associated with any of the 5 CoRs in this cohort, especially RISK6, Suliman4, or Maetzdorf4, it is likely that there was little incipient TB in the Step study, and so these CoRs were detecting ISGs provoked by stimuli other than *Mtb* infection. The *Mtb*-specific cellular responses that define LTBI are well-known to persist despite LTBI treatment or spontaneous clearance of *Mtb* infection[41, 42], and therefore persons with LTBI may not been expressing differential ISG or other gene transcription.

The results of the exploratory analyses provide some evidence that a transcriptomic biomarker could predict HIV risk, regardless of *Mtb* infection. The Sweeney3 signature best predicted odds of acquiring HIV in unadjusted and adjusted analyses, and in the LTBI-negative, but not the LTBI-positive group. This three-gene set predicts the presence of active TB disease versus LTBI with better accuracy (86% sensitivity, 86% specificity) than most combinations of clinical prediction tools, and with similar sensitivity to GeneXpert-MTB RIF sputum tests.[43, 44] Because the three genes, GBP5, DUSP3, and KLF2, are associated with immune signaling pathways and macrophage regulation[45-47], this gene set may detect a high-risk systemic immune status related to genital or gastrointestinal infection or altered microbiome composition, which could also be differentially associated with LTBI status. In contrast, the RESPONSE5 profile evaluates differential gene expression that predicts cure after TB treatment, wherein a high score represents higher innate immune activation[28], and higher scores were associated with lower odds of HIV acquisition in this cohort. These findings suggest that *Mtb* infection and polyfunctional *Mtb* antigen-specific T-cell activation are not associated directly with HIV risk, but that other unmeasured exposures may ultimately activate these same host transcriptional pathways and explain the observed association between CoR signatures and HIV acquisition.

Our study has several limitations, the foremost of which was lack of availability of stored PBMC close to the time of HIV acquisition in some cases. Some samples were collected more than one year prior to documented HIV diagnosis. Due to wide intervals between study visits (up to 6 months between visits), many persons likely acquired HIV much closer to the sampling timepoint than indicated by their diagnosis visit, but the timing of HIV acquisition is not clearly pinpointed. That said, CoR signatures are able to predict progression to incident TB up to 24 months prior to clinical disease, and show accurate prediction within 1 year.[17, 26] As the parent Step study occurred within some countries with moderate or high TB prevalence, there is a possible risk that interval *Mtb* infection or sub-clinical reactivation occurred between sampling and HIV outcome. Additionally, LTBI status was not determined in the Step study; thus, we were unable to use clinically accepted measures of LTBI status, such as IGRA or TST. Having access to a single blood sample limited our ability to assess interval LTBI status conversion or reversion prior to HIV acquisition, and there is a possibility of other unevaluated infections or other confounders. Nonetheless, the Step study represents a rare opportunity to address this issue as there are few, if any, cohorts in which *Mtb* infection status, future HIV outcome, and longitudinal cryopreserved specimens are available. Instead, we used a rigorous *Mtb*-antigen-specific flow cytometry assay that provided richer descriptive data, not only about LTBI status, but about the degree and quality of *Mtb* responses. Other strengths of this study include rigorous characterization of study participants as part of the parent Step study, and novel application of TB CoR signatures.

## Conclusions

In this study, we found no evidence that LTBI or polyfunctional Mtb-antigen-specific T cell responses were associated with risk of HIV acquisition in a population at high risk for HIV. Based on this translational study we would not expect that treating LTBI in persons at risk for HIV would decrease risk of HIV acquisition substantially, especially in the context of increasingly effective HIV pre-exposure prophylaxis (PrEP) options. Treating LTBI has other intrinsic benefits, including prevention of TB disease and *Mtb* transmission, especially in those who have been diagnosed with HIV. However, the exploratory analyses demonstrated that transcriptomic signatures could predict HIV risk above and beyond known behavioral and viral co-infection risk factors identified in the Step study and many prior studies. To our knowledge there is little data on differential gene regulation associated with HIV risk. While we found variable associations with some purpose-designed TB CoR signatures, global transcriptomic analysis could assist in discovery of similar, simpler HIV CoR signatures. Although such HIV CoR signatures would be unlikely to replace patient-reported indications for PrEP and other prevention measures, such signatures could be beneficial in risk-stratifying participants within HIV prevention and vaccine studies or testing for high-risk post-vaccine immune responses in early-phase trial volunteers. Such signatures could help identify a vaccine that might induce risky immune states for HIV acquisition, such as occurred in the Step study, before moving the vaccine candidate to larger trials in HIV-exposed populations.

## Supporting information

Supplementary Tables [[supplements/267470_file02.docx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors

## Funding

This research was funded by a 2018 CFAR New Investigator Award from the University of Washington / Fred Hutch Center for AIDS Research, an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK.

This work has been presented in part at the 2020 CFAR national meeting, virtually in San Diego, USA Nov 4, 2020.

Contact information: Dr. Bender Ignacio, rbi13{at}uw.edu, Address: UW ACTU, Harborview Medical Center, Box 359929, Seattle, WA 98104

## Acknowledgements

We thank the Step study volunteers and the study staff for their contributions, especially Ashley Clayton, Lisa Bunts, and Todd Haight for facilitating HVTN ancillary studies. We thank Dr. Michael Robertson and Merck Research Laboratories for their contributions to the Step study. We acknowledge Erik Layton and Chetan Seshadri for technical assistance with flow cytometry.

*   Received December 8, 2021.
*   Revision received December 8, 2021.
*   Accepted December 8, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). The Journal of infectious diseases. 2012;206(2):258–66. Epub 2012/05/09. doi: 10.1093/infdis/jis342. PubMed PMID: 22561365; PubMed Central PMCID: PMCPmc3490694.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jis342&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22561365&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

2.  2.Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (London, England). 2008;372(9653):1881–93. Epub 2008/11/18. doi: 10.1016/s0140-6736(08)61591-3. PubMed PMID: 19012954; PubMed Central PMCID: PMCPMC2721012.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(08)61591-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19012954&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

3.  3.Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-gamma secretion with increased HIV-1 infection risk: a cohort-based modeling study. PloS one. 2014;9(11):e108631. Epub 2014/11/05. doi: 10.1371/journal.pone.0108631. PubMed PMID: 25369172; PubMed Central PMCID: PMCPmc4219669.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0108631&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25369172&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

4.  4.Kahle EM, Bolton M, Hughes JP, Donnell D, Celum C, Lingappa JR, et al. Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples. The Journal of infectious diseases. 2015;211(9):1451–60. Epub 2014/11/13. doi: 10.1093/infdis/jiu621. PubMed PMID: 25389306; PubMed Central PMCID: PMCPmc4447828.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiu621&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25389306&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

5.  5.Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, et al. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. The Journal of infectious diseases. 2012;206(7):993–1001. Epub 2012/07/26. doi: 10.1093/infdis/jis465. PubMed PMID: 22829639; PubMed Central PMCID: PMCPmc3501691.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jis465&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22829639&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

6.  6.Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. The Journal of infectious diseases. 2002;185(1):45–52. Epub 2002/01/05. doi: 10.1086/338231. PubMed PMID: 11756980.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/338231&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11756980&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000172722600006&link_type=ISI) 

7.  7.Kroidl I, Saathoff E, Maganga L, Makunde WH, Hoerauf A, Geldmacher C, et al. Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study. Lancet (London, England). 2016;388(10054):1912–20. Epub 2016/10/19. doi: 10.1016/s0140-6736(16)31252-1. PubMed PMID: 27495354.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(16)31252-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27495354&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

8.  8.Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (London, England). 2006;20(1):73–83. Epub 2005/12/06. PubMed PMID: 16327322.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/01.aids.0000198081.09337.a7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16327322&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000234224400011&link_type=ISI) 

9.  9.Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. American Journal of Reproductive Immunology. 2011;65(3):308–16.
    
    

10. 10.Kaul R, Pettengell C, Sheth P, Sunderji S, Biringer A, MacDonald K, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. Journal of reproductive immunology. 2008;77(1):32–40.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jri.2007.02.002&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17395270&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000253431400005&link_type=ISI) 

11. 11.Abdool Karim SS, Baxter C, Passmore JAS, McKinnon LR, Williams BL. The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women. Journal of the International AIDS Society. 2019;22(5):e25300.
    
    

12. 12.W.H.O. Global tuberculosis report 2020. 2020.
    
    

13. 13.Kyu HH, Maddison ER, Henry NJ, Mumford JE, Barber R, Shields C, et al. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. The Lancet Infectious Diseases. 2018;18(3):261–84.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(17)30703-X&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

14. 14.Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS medicine. 2016;13(10):e1002152.
    
    

15. 15.Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS pathogens. 2017;13(11):e1006687.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.ppat.1006687&link_type=DOI) 

16. 16.Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, et al. Considerations for biomarker-targeted intervention strategies for TB prevention. Tuberculosis. 2018;109:61–8.
    
    

17. 17.Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet (London, England). 2016;387(10035):2312–22. Epub 2016/03/28. doi: 10.1016/s0140-6736(15)01316-1. PubMed PMID: 27017310.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(15)01316-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27017310&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

18. 18.Garrait V, Cadranel J, Esvant H, Herry I, Morinet P, Mayaud C, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. The Journal of Immunology. 1997;159(6):2824–30.
    
    

19. 19.He X, Eddy JJ, Jacobson KR, Henderson AJ, Agosto LM. Enhanced Human Immunodeficiency Virus-1 Replication in CD4+ T Cells Derived From Individuals With Latent Mycobacterium tuberculosis Infection. The Journal of infectious diseases. 2020;222(9):1550–60.
    
    

20. 20.Thayil SM, Ho Y-C, Bollinger RC, Blankson JN, Siliciano RF, Karakousis PC, et al. Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathway. PloS one. 2012;7(7):e41093.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0041093&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22844428&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

21. 21.Skerry C, Klinkenberg LG, Page KR, Karakousis PC. TLR2-Modulating Lipoproteins of the Mycobacterium tuberculosis Complex Enhance the HIV Infectivity of CD4+ T Cells. PloS one. 2016;11(1):e0147192. Epub 2016/01/26. doi: 10.1371/journal.pone.0147192. PubMed PMID: 26807859; PubMed Central PMCID: PMCPmc4725761.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0147192&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26807859&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

22. 22.Jensen K, dela Pena-Ponce MG, Piatak M, Shoemaker R, Oswald K, Jacobs WR, et al. Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine. Clinical and Vaccine Immunology : CVI. 2017;24(1). doi: 10.1128/cvi.00360-16. PubMed PMID: 27655885; PubMed Central PMCID: PMCPmc5216431.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY2RsaSI7czo1OiJyZXNpZCI7czoxNDoiMjQvMS9lMDAzNjAtMTYiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMi8wOC8yMDIxLjEyLjA4LjIxMjY3NDcwLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

23. 23.Organization WH. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management.
    
    

24. 24.Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M, et al. MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2008;73(10):926–30.
    
    

25. 25.Darboe F, Mbandi SK, Thompson EG, Fisher M, Rodo M, van Rooyen M, et al. Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis. 2018;108:124–6. doi: [https://doi.org/10.1016/j.tube.2017.11.001](https://doi.org/10.1016/j.tube.2017.11.001).
    
    

26. 26.Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific reports. 2020;10(1):1–21.
    
    

27. 27.Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. The Lancet Respiratory Medicine. 2016;4(3):213–24.
    
    

28. 28.Thompson EG, D. Y, Malherbe ST, Shankar S, Braun J, Valvo J, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis. 2017;107:48–58.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

29. 29.Suliman S, Thompson EG, Sutherland J, Weiner 3rd J, Ota MO, Shankar S, et al. Four-gene pan-African blood signature predicts progression to tuberculosis. American journal of respiratory and critical care medicine. 2018;197(9):1198–208.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

30. 30.Maertzdorf J, Weiner J, Mollenkopf H-J, Network T, Bauer T, Prasse A, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proceedings of the National Academy of Sciences. 2012;109(20):7853–8.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMToiMTA5LzIwLzc4NTMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMi8wOC8yMDIxLjEyLjA4LjIxMjY3NDcwLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

31. 31.Cosmi L, Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, et al. Detection by flow cytometry of ESAT-6-and PPD-specific circulating CD4+ T lymphocytes as a diagnostic tool for tuberculosis. International archives of allergy and immunology. 2007;143(1):1–9. Epub 2006/12/28. doi: 10.1159/000098220. PubMed PMID: 17191004.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1159/000098220&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17191004&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

32. 32.Tesfa L, Koch FW, Pankow W, Volk HD, Kern F. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Cytometry Part B, Clinical cytometry. 2004;60(1):47–53. Epub 2004/06/29. doi: 10.1002/cyto.b.20007. PubMed PMID: 15221869.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/cyto.b.20007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15221869&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

33. 33.Papageorgiou CV, Anastasopoulos A, Ploussi M, Leventopoulos M, Karabela S, Fotiadis K, et al. Flow cytometry analysis of CD4+ IFN-γ+ T-cells for the diagnosis of mycobacterium tuberculosis infection. Cytometry Part B: Clinical Cytometry. 2016;90(3):303–11.
    
    

34. 34.Lee J, Lee SY, Won DI, Cha SI, Park JY, Kim CH. Comparison of whole-blood interferon-γ assay and flow cytometry for the detection of tuberculosis infection. Journal of Infection. 2013;66(4):338–45.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jinf.2012.08.020&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23010554&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000315860500006&link_type=ISI) 

35. 35.Sauzullo I, Scrivo R, Mengoni F, Ermocida A, Coppola M, Valesini G, et al. Multi-functional flow cytometry analysis of CD 4+ T cells as an immune biomarker for latent tuberculosis status in patients treated with tumour necrosis factor (TNF) antagonists. Clinical & Experimental Immunology. 2014;176(3):410–7.
    
    

36. 36.Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotech. 2015;33(6):610–6. doi: 10.1038/nbt.3187 [http://www.nature.com/nbt/journal/v33/n6/abs/nbt.3187.html#supplementary-information](http://www.nature.com/nbt/journal/v33/n6/abs/nbt.3187.html#supplementary-information).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nbt.3187&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26006008&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

37. 37.Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, et al. TLR activation pathways in HIV-1-exposed seronegative individuals. Journal of immunology (Baltimore, Md : 1950). 2010;184(5):2710–7. Epub 2010/02/04. doi: 10.4049/jimmunol.0902463. PubMed PMID: 20124101.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiamltbXVub2wiO3M6NToicmVzaWQiO3M6MTA6IjE4NC81LzI3MTAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8xMi8wOC8yMDIxLjEyLjA4LjIxMjY3NDcwLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

38. 38.Shah JA, Berrington WR, Vary JC Jr.., Wells RD, Peterson GJ, Kunwar CB, et al. Genetic Variation in Toll-Interacting Protein Is Associated With Leprosy Susceptibility and Cutaneous Expression of Interleukin 1 Receptor Antagonist. The Journal of infectious diseases. 2016;213(7):1189–97. Epub 2015/11/28. doi: 10.1093/infdis/jiv570. PubMed PMID: 26610735; PubMed Central PMCID: PMCPMC4779304.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiv570&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26610735&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

39. 39.Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, et al. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PloS one. 2015;10(9):e0136626. Epub 2015/09/04. doi: 10.1371/journal.pone.0136626. PubMed PMID: 26332672; PubMed Central PMCID: PMCPMC4558095 Allergy and Infectious Diseases (NIAID). DVM and MR are employees of Merck. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0136626&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26332672&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

40. 40.Benjamini Y, Heller R, Yekutieli D. Selective inference in complex research. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences. 2009;367(1906):4255–71. doi: 10.1098/rsta.2009.0127.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1098/rsta.2009.0127&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19805444&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

41. 41.Kim OH, Jo KW, Park S, Jo YH, Kim MN, Sung H, et al. Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection. PloS one. 2020;15(6):e0234700. Epub 2020/06/17. doi: 10.1371/journal.pone.0234700. PubMed PMID: 32544206; PubMed Central PMCID: PMCPMC7297367.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0234700&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32544206&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

42. 42.Xin H, Cao X, Zhang H, Liu J, Pan S, Li X, et al. Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment. Clin Microbiol Infect. 2020;26(11):1555.e1-.e7. Epub 2020/02/18. doi: 10.1016/j.cmi.2020.02.009. PubMed PMID: 32062048.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cmi.2020.02.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32062048&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

43. 43.Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews. 2019;(6).
    
    

44. 44.Moreira FMF, Verma R, Pereira dos Santos PC, Leite A, da Silva Santos A, de Araujo RCP, et al. Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study. EClinicalMedicine. 2021;33. doi: 10.1016/j.eclinm.2021.100776. PubMed PMID: 100776.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.eclinm.2021.100776&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=100776&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

45. 45.Feng J, Cao Z, Wang L, Wan Y, Peng N, Wang Q, et al. Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection. Journal of Innate Immunity. 2017;9(4):419–35. doi: 10.1159/000460294.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1159/000460294&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28376501&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F12%2F08%2F2021.12.08.21267470.atom) 

46. 46.Singh P, Dejager L, Amand M, Theatre E, Vandereyken M, Zurashvili T, et al. DUSP3 Genetic Deletion Confers M2-like Macrophage–Dependent Tolerance to Septic Shock. The Journal of Immunology. 2015;194(10):4951–62. doi: 10.4049/jimmunol.1402431.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiamltbXVub2wiO3M6NToicmVzaWQiO3M6MTE6IjE5NC8xMC80OTUxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMTIvMDgvMjAyMS4xMi4wOC4yMTI2NzQ3MC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

47. 47.Paik S, Kim JK, Silwal P, Sasakawa C, Jo E-K. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cellular & Molecular Immunology. 2021;18(5):1141–60. doi: 10.1038/s41423-021-00670-3.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41423-021-00670-3&link_type=DOI)